title: The safety and tolerability of the second-line injectable antituberculosis drugs in children.
abstract: A growing number of children globally are being treated for multidrug-resistant tuberculosis (MDR-TB). The second-line injectable antituberculosis medications amikacin, kanamycin and capreomycin, traditionally a mainstay of MDR-TB treatment, cause important adverse effects including permanent sensorineural hearing loss, nephrotoxicity, electrolyte abnormalities, injection pain and local injection site complications. Areas covered: To characterize the safety and tolerability of the second-line injectables in children treated for MDR-TB, we reviewed data on the mechanism of injectable associated adverse effects, risk factors for their development, and the incidence of injectable-associated adverse effects in adults and children treated for MDR-TB. Expert opinion: Despite a substantial evidence base in adults demonstrating the frequent and potentially serious adverse effects of second-line injectables, important knowledge gaps remain. Improved characterization of the incidence of injectable-associated adverse effects will inform rational guidance on monitoring children with TB on injectables. Eliminating the need for injectables in MDR-TB treatment regimens is a high priority, and will rely on the use of novel antituberculosis TB drugs. Strategies to reduce the risk of adverse effects of injectables, if used, deserve evaluation. This includes evaluation of potentially otoprotective medications N-acetylcysteine or aspirin, high frequency hearing screening for earlier detection of ototoxicity and therapeutic drug monitoring.
authors.affiliation: a Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences , Stellenbosch University , Tygerberg , South Africa.
authors.forename: Anthony J
authors.initials: AJ
authors.lastname: Garcia-Prats
authors.affiliation: a Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences , Stellenbosch University , Tygerberg , South Africa.
authors.forename: H Simon
authors.initials: HS
authors.lastname: Schaaf
authors.affiliation: a Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences , Stellenbosch University , Tygerberg , South Africa.
authors.forename: Anneke C
authors.initials: AC
authors.lastname: Hesseling
mesh_terms: D000328:Adult; D000583:Amikacin / Q000008:administration & dosage / Q000009:adverse effects; D000818:Animals; D000995:Antitubercular Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002207:Capreomycin / Q000008:administration & dosage / Q000009:adverse effects; D002648:Child; D016903:Drug Monitoring; D006801:Humans; D007267:Injections; D007612:Kanamycin / Q000008:administration & dosage / Q000009:adverse effects; D012307:Risk Factors; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*
chemical_list: D000995:Antitubercular Agents; D002207:Capreomycin; D007612:Kanamycin; D000583:Amikacin
keywords: Injectable; amikacin; capreomycin; children; kanamycin; multidrug-resistant; ototoxicity; safety; tuberculosis